A study to evaluate the safety and immunogenicity of a candidate Ebola Vaccine in children

Mise à jour : Il y a 5 ans
Référence : EUCTR2014-004714-28

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the safety and reactogenicity of a single IM dose of the ChAd3 EBO-Z vaccine, overall and in children aged 1 to 5, 6 to 12, and 13 to 17 years, separately.


Critère d'inclusion

  • Primary immunisation against Ebola Zaire virus on healthy volunteers

Liens